Hospital treatment of congestive heart failure. Management according to hemodynamic profile
- PMID: 685990
- DOI: 10.1016/0002-9343(78)90707-6
Hospital treatment of congestive heart failure. Management according to hemodynamic profile
Abstract
Selection of therapy for subjects with acute congestive dardiac failure usually involves a choice among a diuretic, a vasodilator and an inotropic agent. Three principal questions are involved in the decision: (1) Is cardiac out normal or depressed? (2) Is blood pressure normal or depressed? (3) is regional myocardial ischemia present? Diuretics are safe and easy to administer, but they do not increase cardiac output or relieve hypoperfusion. Inotropic agents increase cardiac output but differ widely in their effects on blood pressure: selection of specific agents is influenced by their blood pressure effect. All inotropic agents, however, potentially aggravate regional myocardial ischemia. In ischemic heart failure, therefore, vasodilators which also increase cardiac output, may be chosen. Vasodilator administration is in turn limited by the decrease in arterial pressure which accompanies increasing infusion rate. When these three questions are considered in combination, an effective therapeutic regimen can be identified. Thus, congestion without hypoperfusion requires a diuretic if blood pressure is normal; and a vasodilator when blood pressure is increased. In the presence of congestion with hypoperfusion, a vasodilator is employed if blood pressure is normal; and a positive inotropic drug when blood pressure is depressed.
Similar articles
-
Selection of vasodilator, inotropic or combined therapy for the management of heart failure.Am J Med. 1978 Jul;65(1):181-8. doi: 10.1016/0002-9343(78)90708-8. Am J Med. 1978. PMID: 685992
-
Mechanisms of beneficial effects of vasodilators and inotropic stimulation in the experimental failing ischemic heart.Am J Med. 1978 Jul;65(1):189-96. doi: 10.1016/0002-9343(78)90709-x. Am J Med. 1978. PMID: 685993
-
Rationale and use of vasodilators in the management of congestive heart failure.Am Heart J. 1979 Apr;97(4):519-26. doi: 10.1016/0002-8703(79)90402-2. Am Heart J. 1979. PMID: 371379 Review. No abstract available.
-
Afterload reduction and cardiac performance. Physiologic basis of systemic vasodilators as a new approach in treatment of congestive heart failure.Am J Med. 1978 Jul;65(1):106-25. doi: 10.1016/0002-9343(78)90700-3. Am J Med. 1978. PMID: 99030 Review.
-
Hemodynamic responsiveness to short- and long-acting vasodilators in left ventricular failure.Am J Med. 1978 Jul;65(1):126-33. doi: 10.1016/0002-9343(78)90701-5. Am J Med. 1978. PMID: 685986
Cited by
-
Diuretics. Clinical pharmacology and therapeutic use (Part II).Drugs. 1985 Feb;29(2):162-88. doi: 10.2165/00003495-198529020-00003. Drugs. 1985. PMID: 3884320 Review.
-
Value of Echocardiography in the Treatment of Patients With Acute Heart Failure.Front Cardiovasc Med. 2021 Nov 15;8:740439. doi: 10.3389/fcvm.2021.740439. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34869645 Free PMC article. Review.
-
Central venous pressure and pulmonary capillary wedge pressure: fresh clinical perspectives from a new model of discordant and concordant heart failure.Tex Heart Inst J. 2011;38(6):627-38. Tex Heart Inst J. 2011. PMID: 22199422 Free PMC article.
-
Prognosis of Advanced Heart Failure Patients according to Their Hemodynamic Profile Based on the Modified Forrester Classification.J Clin Med. 2022 Jun 24;11(13):3663. doi: 10.3390/jcm11133663. J Clin Med. 2022. PMID: 35806946 Free PMC article.
-
Contributions of cardiac dysfunction and volume status to central haemodynamics in chronic heart failure.Eur J Heart Fail. 2021 Jul;23(7):1097-1105. doi: 10.1002/ejhf.2121. Epub 2021 Feb 21. Eur J Heart Fail. 2021. PMID: 33565251 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources